Mémantine (Ebixa®): A new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease;Mémantine (Ebixa®): Une nouvelle stratégie thérapeutique dans le traitement des formes modérément sévères à sévères de la maladie d'Alzheimer

Encephale

Volumn 30, Issue 1, 2004, Pages 69-79

  Gallarda, Th ^a   Loo H ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Alzheimer's disease; Dementia; Glutamate; Memantine; Severe; Vascular dementia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; CALCIUM CHANNEL; DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COST OF ILLNESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; GERMANY; HUMAN; INSOMNIA; MALE; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; DRUG EFFECT; HOSPITALIZATION;

AGED; ALZHEIMER DISEASE; CALCIUM CHANNELS; DOPAMINE AGENTS; HUMANS; MEMANTINE; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 1642346211     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(04)95418-8     Document Type: Article

References (46)

1. BEAR MF, CONNORS BW, PARADISO M. Neurotransmetteurs: Organisation anatomo-biochimique du système nerveux, in Neurosciences. A la découverte du cerveau, Éditions Pradel, traduction et adaptation française, André Nieoullon, 1997: 122-150.
2. CACABELOS R, TAKEDA M, WINBLAD B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriat Psychiatry 1999; 14: 3-47.
3. CUMMINGS JL, MEGA M, GRAY K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
4. DANYSZ W, PARSONS CG, MÖBIUS H-J et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 2000; 2: 85-97.
5. DARTIGUES JF, HELMER C, DUBOIS B et al. Alzheimer's disease: a public health problem: yes but a priority? Rev Neurol 2002; 158 (3): 311-5.
6. DITZLER K. Efficacy and tolerability of memantine in patients with dementia syndrome-A double-blind, placebo-controlled trial. Arzneim-Forsch/drug Res 1991; 41 (11): 773-80.
7. DUBOIS B. In: Les nouveaux défis de la maladie d'Alzheimer (préface), Bilans et prospectives, Coordination Bruno Dubois, Ouvrage collectif, 2003, 283 p.
8. DUTAR P. Système cholinergique et traitement de la maladie d'Alzheimer. In: Michel BF, Epelbaum J, Heim M, eds. Neuroendocrinologie des démences. Marseille: Solal éditeur, 2001; 183-200.
9. ÉVALUATION COGNITIVE DES DÉMENCES SÉVÈRES SIB (Severe Impairment Battery), Version française GRECO, Éditions et Applications Psychologiques, EAP, 2001.
10. FELDMAN H, GAUTHIER S, HECKER MD et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
11. FELDMAN H, GRUNDMAN M. Symptomatic treatments for Alzheimer's disease. In: Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. Martin Dunitz 1999; 249-68.
12. FERRIS SH, SCHMIDT F, DOODY R et al. Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced Alzheimer's disease, presented at the annual meeting of the American College of Neuropsychopharmacology. Waikoloa Village, December 9-13, 2001.
13. FOLSTEIN MF, FOLSTEIN SE, McHUGH PR. « Mini Mental State »: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975; 12: 189-98.
14. FRATIGLIONI L, ROCCA W. Epidemiology of dementia. In: Boller F, Grafman J, eds. Handbook of Neuropsychology. Amsterdam: Elsevier 2001, vol 6, chapter 10.
15. er Congrès de l'Encéphale, 10 janvier 2003, Encephale, XXX.
16. er Congrès de l'Encéphale, 10 janvier 2003, Encéphale, XXX.
17. GIRARD JF, CANESTRI A. La maladie d'Alzheimer, septembre 2000, dit rapport Girard. Rapport commandé par le ministère de l'Emploi et de la Solidarité, Secrétariat d'État à la Santé et l'Action Sociale.
18. GÖRTELMEYER R, ERBLER H. Memantine in the treatment of mild to moderate dementia syndrome-a double-blind placebo-controlled study. Arzneim-Forsch/drug Res 1992; 42 (11): 904-12.
19. HARTMANN S, MÖBIUS HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clini Psychopharmacology 2003; 18 (2): 81-5.
20. HUGHES CB, BERG L, DANZIGER WL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72.
21. JOËL ME. Socio-économie. In: « Les nouveaux défis de la maladie d'Alzheimer » Bilans et prospectives, Coordination Bruno Dubois, Ouvrage collectif, 2003 ou 2002, 283 p.
22. LE DA, LIPTON SA. Potential and current use of N-Methyl-D-Aspartate (NMDA) receptor antagonists in diseases of aging. Drugs and Aging 2001; 18 (10): 717-24.
23. LEBER P, Guidelines for the clinical evaluation of Antidementia Drugs. Washington DC: Food & Drug Administration, 1990.
24. LETENNEUR L, DEQUAE L, JACQMIN H et al. Prévalence de la démence en Gironde (France). Rev Epidemiol Santé Publique 1993; 41: 139-45.
25. NIEOULLON A. Théorie de l'excitotoxicite. Implication potentielle des acides aminés excitateurs dans les processus dégé nératifs. In: Michel BF, Epelbaum J, Heim M, Arnaud-Castiglioni R, eds. Neuroendocrinologie des démences. Marseille: Solal éditeur, 2001: 111-28.
26. OLNEY JW. Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science 1969; 164: 719-21.
27. ORGOGOZO JM, RIGAUD AS, STOFFLER A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-9.
28. PANISSET M, ROUDIER M, SAXTON J et al. Batterie d'évaluation neuropsychologique pour la démence grave. Presse Médicale 1992; 21: 1271-4.
29. PANTEV M, RITTER R, GÖRTELMEYER R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeischrift für Gerontopsychologie und psychiatrie 1993; heft 2, S: 103-17.
30. PARSONS CG, DANYSZ W, QUACK G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998; 11 (9): 523-69.
31. PARSONS CG, DANYSZ W, QUACK G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999; 38: 735-67.
32. PARSONS CG, FRANKIEWICZ T, LAZAREWICZ JW et al. Memantine enhances ischemic tolerance, presented at the eighth International Conference on Alzheimer's disease. Stockolm: Sweden, July 20-25, 2002.
33. RAMAROSON H, HELMER C, BARBERGER-GATEAU P et al. Prévalence de la démence et de la maladie d'Alzheimer chez les personnes âgées de 75 ans et plus: données réactualisé es de la cohorte PAQUID. Rev Neurol 2003; 159 (4): 405-11.
34. REISBERG B, FERRIS SH, ANAND R et al. Functional staging of dementia of the Alzheimer's type. Ann NY Acad Sci 1984; 435: 481-3.
35. REISBERG B, FERRIS SH, DELEON MJ et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
36. REISBERG B, DOODY R, STÖFFLER A et al. Memantine in moderate-to-severe Alzheimer's disease. New Engl J Med 2003; 348 (14): 1333-41.
37. REISBERG B, WINDSCHEIF U, FERRIS SH et al. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6month multicenter randomized controlled trial, presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan: Puerto-Rico, December 10-14, 2000.
38. REISBERG B. Functional Assessment Staging (FAST), Psychopharmacology Bull 1988: 653-9.
39. RÜTHER E, GLASER A, BLEICH S et al. A prospective PMS study to validate the sensitivity for change of the D-Scale in advanced Stages of dementia using the NMDA-antagonist Memantine. Pharmacopsychiatry 2000; 33: 103-8.
40. SAXTON J, McGONIGLE-GIBSON K, SWIHART A et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychological assessment: J Consult Clin Psychology 1990: 2; 298-303.
41. SCHMITT FA, CRAGAR D, ASHFORD JW et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Trans 2002; (Suppl 62): 135-48.
42. TARIOT P, FARLOW M, GROSSBERG G et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 21 Janvier 2004; 291 (3): 317-324.
43. VERNY M, HUGONOT-DIENER L, BOLLER F. Severe dementia and its evaluation: scales for cognition, behavior and overall functioning. In:Boller F, Grafman J, eds. Handbook of Neuropsychology. Elsevier: Amsterdam, vol 6 (Aging and dementia), 2001: 463-74.
44. WIMO A, WINBLAD B, STÖFFLER B et al. Effect of long-term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28-week, randomized, double-blind, placebo-controlled study, presented at the eigth International Conference on Alzheimer's disease. Stockolm: Sweden, July 20-25, 2002.
45. WINBLAD B, MÖBIUS HJ, STÖFFLER A. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neural Transm 2002 (Suppl 62): 217-25.
46. WINBLAD B, PORITIS N. Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatric Psychiatry 1999; 14: 135-46.